Upadacitinib

RED:

NICE TA665 - treatment of severe active rheumatoid arthritis. (Decision date - January 2021)
NICE TA744 - For moderate rheumatoid arthritis. (Decision date - December 2021)
NICE TA768 - Treatment of active psoriatic arthritis in adults who have responded inadequately to, or who are intolerant to ≥1 DMARDs. Upadacitinib may be used as monotherapy or in combination with methotrexate. (Decision date - March 2022)
NICE TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. Adults commissioned by ICS. Adolescents commissioned by NHSE. (Decision date - September 2022)
NICE TA829 - Upadacitinib for treating active ankylosing spondylitis. ICB commissioned. (Decision date - November 2022)
NICE TA856 - Upadacitinib for treating moderately to severely active ulcerative colitis. ICB commissioned. (Decision date - February 2023)
NICE TA861 - For active non-radiographic axial spondyloarthritis. ICB commissioned. (Decision date - March 2023)
NICE TA905 - For previously treated moderately to severely active Crohn’s disease. ICB commissioned. (Decision date - June 2023)

DNP:

Treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Await national guidance. (Decision date - April 2021)
Moderate-to-severe Crohn's disease. Await national guidance. (Decision date - February 2022)

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)